Listen: From the Wire – Paradigm Biopharma CEO and Founder Paul Rennie
From The Wire: Senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals chief executive officer Paul Rennie.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| IF1 | Interest Details | 31/03/25 | ||
| IF1 | Note Deed Poll | 20/03/25 | ||
| IF1 | Pricing Supplement 5.87% Notes due 28 Nov 2034 | 20/03/25 | ||
| IF1 | Pricing Supplement 5.38% Notes due 28 Nov 2030 | 20/03/25 | ||
| IF1 | Information Form and Checklist | 20/03/25 | ||
| IF1 | Appendix 1B | 20/03/25 | ||
| IF1 | Information Memorandum | 20/03/25 | ||
| IF1 | Admission and Commencement as an ASX Debt Listing | 20/03/25 | ||
 (20min delay)
|
|||||
|
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $0 | |||
| Open | High | Low | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | 0 |
